BSD Medical Announces BSD's Hyperthermia Systems Featured at International Scientific Conference on Radiation Oncology Held i...
April 01 2014 - 9:15AM
Business Wire
BSD Medical Corporation (NASDAQ: BSDM) (Company or BSD)
(www.BSDMedical.com), a leading provider of medical systems that
utilize heat therapy to treat cancer, announced today that both the
Company's hyperthermia technology and related cancer treatment
results were featured prominently at an international scientific
conference focused on radiation oncology treatment of cancer. The
conference was hosted by the N.N. Blokhin Cancer Research Center,
Russian Academy of Medical Sciences (Blokhin Cancer Center), the
leading comprehensive cancer center in Russia, and chaired by
Professor Mikhail Davydov MD PhD, President of the Russian Academy
of Medical Sciences and Director of the Blokhin Cancer Center. The
conference, "9th International Scientific Conference – Clinical
Oncoradiology," was held on March 12-14, 2014, in Moscow, Russia.
The Blokhin Cancer Center comprises four separate institutes,
including a 1,600 bed hospital devoted to cancer patients. Blokhin
Cancer Center is the largest cancer center in the world and is part
of the American-Russian Cancer Alliance, which also includes
prominent U.S. cancer treatment centers. The U.S. National Cancer
Institute (NCI) provides the infrastructure for the Alliance.
Dr. Gerhard Sennewald, CEO of Medizintechnik GmbH and BSD’s
distributor in Russia, co-chaired the scientific session focusing
on hyperthermia technology and the clinical benefits of
hyperthermia. Dr. Sennewald also delivered an invited presentation
titled, "MR Image Guided Hyperthermia: Innovative Interventional
Oncology." Dr. Jacoba van der Zee, MD (Erasmus UMS Rotterdam, The
Netherlands) presented her seminal work, "Hyperthermia and
Radiotherapy in the treatment of Cervical and Breast Cancer."
Sultan Rahman, MS (UMS Munich Grosshadern, Germany) gave a
presentation titled, "Hyperthermia and Chemotherapy: Soft Tissue
Sarcoma and Pancreatic Cancer." Mr. Rahman presented the clinical
trial results on hyperthermia and chemotherapy treatment of soft
tissue sarcoma and discussed the ongoing, multicenter, randomized,
"HEAT" trial using hyperthermia and chemotherapy to treat
pancreatic cancer.
“We were excited about the opportunity to showcase BSD's
hyperthermia systems at this prestigious international conference
hosted by the preeminent Blokhin Cancer Center," stated Dr. Gerhard
Sennewald. "Russia and the GIS countries have a long history in the
use of hyperthermia in clinical oncology, and it is always
rewarding to share in their in-depth knowledge of
hyperthermia."
Russia has a population of 149 million and is a potentially
lucrative market for medical device companies. The Russian market
for medical equipment and supplies is estimated at $6 billion,
which puts the Russian market among the top 20 in the world.
Approximately 73% of the medical equipment market in Russia is
supplied by non-Russian manufacturers, with the United States,
Germany, Japan, and China the leading suppliers.
About BSD Medical Corporation
BSD Medical Corporation develops, manufactures, markets and
services systems to treat cancer and benign diseases using heat
therapy, which is delivered using focused radiofrequency (RF) and
microwave energy. BSD’s product lines include both hyperthermia and
ablation treatment systems. BSD’s hyperthermia cancer treatment
systems, which have been in use for several years in the United
States, Europe and Asia, are used to treat certain tumors with heat
(hyperthermia) while increasing the effectiveness of other
therapies such as radiation therapy. BSD’s microwave ablation
system has been developed as a stand-alone therapy to employ
precision-guided microwave energy to ablate (destroy) soft tissue.
The Company has developed extensive intellectual property, multiple
products in the market and established distribution in the United
States, Europe and Asia. Certain of the Company’s products have
received regulatory approvals and clearances in the United States,
Europe and China. For further information visit BSD Medical's
website at www.BSDMedical.com.
This press release may be deemed to contain forward-looking
statements, which are subject to the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995, including the
expected use of proceeds relating to the recently completed
offering. Readers are cautioned that these forward-looking
statements are only predictions and may differ materially from
actual future events or results due to a variety of factors,
including, among other things, the demand for the Company’s
products, the ability of the Company to produce the products to
meet the demand, global economic conditions and uncertainties in
the geopolitical environment and other risk factors set forth in
the Company’s most recent reports on Form 10-K and Form 10-Q. Any
forward-looking statements in this release are based on limited
information currently available to the Company, which is subject to
change, and the Company will not necessarily update the
information.
.
BSD Medical CorporationWilliam Barth,
801-972-5555investor@bsdmc.comfax: 801-972-5930